| 英文摘要 |
Background: Nalbuphine sebacate (Naldebain®), an intramuscular prodrug of nalbuphine, offers longacting relief for postoperative pain. This study evaluates the effi cacy and safety of Naldebain®for acute pain management postelective cesarean delivery.
Methods: A retrospective review was conducted on 30 parturients who received epidural anesthesia for elective cesarean delivery. Group C (n = 20) received patient-controlled epidural analgesia (PCEA) alone, while Group N (n = 10) was administered a single 150 mg intramuscular dose of Naldebain®alongside PCEA. Postoperative pain intensity was assessed using the numeric rating scale at various intervals, with analgesic consumption, muscle tone, side effects, and patient satisfaction also recorded and analyzed.
Results: Group N exhibited a significant reduction in PCEA fentanyl consumption on the first day compared to Group C (52.9±18.7 vs. 70.8±23.7 mcg, P = 0.045). Pain intensity did not signifi cantly differ between the groups over three days postsurgery. Both groups were comparable regarding muscle tone, side effects, and overall satisfaction although fewer patients in Group N required rescue pain control (20% vs. 60%, P = 0.038).
Conclusion: The combination of a single-dose Naldebain®with PCEA showed a fentanyl-sparing effect on the first postoperative day and decreased the need for rescue analgesics during PCEA without an increase in adverse events. |
本站僅提供期刊文獻檢索。
